Glycosylated Fibronectin as a First-Trimester Biomarker for Prediction of Gestational Diabetes
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the potential clinical utility of serum biomarkers for first-trimester prediction of gestational diabetes mellitus (GDM). METHODS: Maternal serum concentrations of glycosylated (Sambucus nigra lectin-reactive) fibronectin, adiponectin, sex hormone-binding globulin, placental lactogen, and high-sensitivity C-reactive protein (CRP) were measured at 5-13 weeks of gestation in a case-control study of 90 pregnant women with subsequent development of GDM and in 92 control group participants. Ability to detect GDM was assessed using logistic regression modeling and receiver operating characteristic (ROC) curves. Classification performance and positive and negative predictive values were reported at specific thresholds. Glycosylated fibronectin variation across trimesters was evaluated using a serial-measures analysis of 35 nondiabetic control group participants. RESULTS: First-trimester serum concentrations of glycosylated fibronectin, adiponectin, high-sensitivity CRP, and placental lactogen were significantly associated (P<.001) with GDM. After adjustment for maternal factors and other biomarkers, glycosylated fibronectin demonstrated an independent association with GDM (P<.001). Adiponectin, high-sensitivity CRP, and placental lactogen demonstrated modest classification performance compared with glycosylated fibronectin (respectively: area under the curve [AUC] 0.63; 95% confidence interval [CI] 0.53-0.71; AUC 0.68; 95% CI 0.60-0.76; and AUC 0.67, 95% CI 0.59-0.75; compared with AUC 0.91; 95% CI 0.87-0.96). Glycosylated fibronectin levels above a threshold of 120 mg/L correctly identified 57 GDM case group participants with a positive predictive value of 63% (95% CI 53-72%) and a negative predictive value of 95% (95% CI 94-95%) at a population prevalence of 12%. There was no association between sex hormone-binding globulin and GDM. CONCLUSION: First-trimester glycosylated fibronectin is a potential pregnancy-specific biomarker for early identification of women at risk for GDM. LEVEL OF EVIDENCE: II.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
ACOG Practice Bulletin No. 30: Gestational Diabetes
(2001) · Obstetrics & Gynecology · doi:10.1097/00006250-200109000-00037 · Cited by 301
RetractedInternational Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60731-5 · Cited by 3,253 · cited 1×
“In addition, 5–10% of women with GDM are found to have diabetes immediately after pregnancy, and women who have had GDM have a 34% risk of development of diabetes within the next 2–11 years compared with a risk of 5% for women without GDM in previous pregnancies.(22) Children of mothers with GDM have a 21% risk of dev…”
BackgroundEffect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Increasing Prevalence of Gestational Diabetes Mellitus
Ferrara, A. (2007) · Diabetes Care · doi:10.2337/dc07-s206 · Cited by 1,171
Glucose challenge test for detecting gestational diabetes mellitus: a systematic review
van Leeuwen, M., Louwerse, M., Opmeer, B., Limpens, J., Serlie, M., Reitsma, J., & Mol, B. (2012) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2011.03254.x · Cited by 110
Cited by
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Zhu, C., Yang, H., Geng, Q., Ma, Q., Long, Y., Zhou, C., & Chen, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126490 · Cited by 120
Biochemical and Molecular Biomarkers: Unraveling Their Role in Gestational Diabetes Mellitus
Karami, M., Mousavi, S. H., Rafiee, M., Heidari, R., & Shahrokhi, S. Z. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00980-8 · Cited by 33
Metadata
- Authors
- Rasanen, J. P., Snyder, C. K., Rao, P. V., Mihalache, R., Heinonen, S., Gravett, M. G., Roberts, C. T., & Nagalla, S. R.
- Venue
- Obstetrics & Gynecology
- Published
- 2013-09
- Volume
- 122
- Issue
- 3
- Pages
- 586-594
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2098805320
- Cited by
- 78
- References
- 8
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycosylated Fibronectin as a First-Trimester Biomarker for Prediction of Gestational Diabetes. https://app.cochat.ai/papers/10.1097/aog.0b013e3182a0c88b
- The paper
- Rasanen, J. P., Snyder, C. K., Rao, P. V., Mihalache, R., Heinonen, S., Gravett, M. G., Roberts, C. T., & Nagalla, S. R. (2013). Glycosylated Fibronectin as a First-Trimester Biomarker for Prediction of Gestational Diabetes. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0b013e3182a0c88b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.